Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP ‐531, a first‐in‐class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes
Authors:
- 26 May 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (9) , 868-874
Abstract
Aim: To explore the safety, pharmacokinetics and pharmacodynamics in humans of the unacylated ghrelin analogue AZP ‐531, designed to improve glycaemic control and reduce weight. Methods: Assessments, including glucose measurements, were performed in a three‐part randomized study. In P art A , healthy subjects [n = 44, age 18–50 years, body mass index ( BMI ) 20–28 kg/m 2 ] received a single subcutaneous dose of 0.3, 3, 15, 30, 60 or 120 µg/kg AZP ‐531 or placebo. In P art B , overweight/obese subjects (n = 32, age 18–65 years, BMI 28–38 kg/m 2 ) and in P art C , patients with type 2 diabetes [ T2D ; n = 36, age 18–65 years, BMI 20–40 kg/m 2 , glycated haemoglobin ( HbA1c ) 7–10%] received AZP ‐531 or placebo for 14 days (daily doses of 3, 15, 30 or 60 µg/kg and 15, 2 × 30 or 60 µg/kg, respectively). Results: AZP ‐531 was well tolerated. Single‐ and multiple‐dose pharmokinetic variables were similar. Maximum AZP ‐531 concentrations were typically reached at 1 h post‐dose. Observed maximum concentration (C max ) and area under the curve were dose‐proportional. The mean terminal half‐life (t 1/2 ) was 2–3 h. In P art B , AZP ‐531 doses of ≥15 µg/kg significantly improved glucose concentrations, without increasing insulin levels, suggesting an insulin‐sensitizing effect. AZP ‐531 decreased mean body weight by 2.6 kg (vs 0.8 kg for placebo). In P art C , glucose variables improved in all groups, including placebo, suggesting a study effect in uncontrolled patients at baseline. Notwithstanding, AZP ‐531 60 µg/kg reduced HbA1c by 0.4% (vs 0.2% for placebo) and body weight by 2.1 kg (vs 1.3 kg for placebo). Conclusions: AZP ‐531 was well tolerated in this first‐in‐human study. Its pharmacokinetic profile, suitable for once‐daily dosing, and metabolic effects support further clinical development for T2D .Keywords
Funding Information
- Alizé Pharma
This publication has 22 references indexed in Scilit:
- Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels?European Journal of Endocrinology, 2014
- Des‐acyl ghrelin analogs prevent high‐fat‐diet‐induced dysregulation of glucose homeostasisThe FASEB Journal, 2013
- In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analoguesEuropean Journal of Pharmaceutical Sciences, 2012
- Metabolic effects of overnight continuous infusion of unacylated ghrelin in humansEuropean Journal of Endocrinology, 2012
- Unacylated Ghrelin Rapidly Modulates Lipogenic and Insulin Signaling Pathway Gene Expression in Metabolically Active Tissues of GHSR Deleted MicePLOS ONE, 2010
- Des-Acyl Ghrelin Has Specific Binding Sites and Different Metabolic Effects from Ghrelin in CardiomyocytesEndocrinology, 2010
- Effect of Des-acyl Ghrelin on Adiposity and Glucose MetabolismEndocrinology, 2008
- Ghrelin octanoylation mediated by an orphan lipid transferaseProceedings of the National Academy of Sciences, 2008
- Identification of the Acyltransferase that Octanoylates Ghrelin, an Appetite-Stimulating Peptide HormoneCell, 2008
- Ghrelin is a growth-hormone-releasing acylated peptide from stomachNature, 1999